PTC Therapeutics (PTCT) Expected to Announce Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT) is projected to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($1.12) per share and revenue of $248.99 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $50.02 on Tuesday. The company has a market capitalization of $3.86 billion, a PE ratio of -8.42 and a beta of 0.62. PTC Therapeutics has a 1-year low of $24.00 and a 1-year high of $54.16. The business has a 50-day moving average of $46.70 and a 200-day moving average of $41.75.

Insider Activity

In related news, insider Neil Gregory Almstead sold 1,300 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $65,130.00. Following the sale, the insider now owns 101,931 shares of the company’s stock, valued at approximately $5,106,743.10. This trade represents a 1.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Mark Elliott Boulding sold 85,600 shares of PTC Therapeutics stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $52.26, for a total value of $4,473,456.00. Following the completion of the sale, the vice president now directly owns 92,389 shares in the company, valued at $4,828,249.14. This represents a 48.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 218,590 shares of company stock valued at $11,264,023 in the last 90 days. 5.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

PTCT has been the topic of a number of research analyst reports. The Goldman Sachs Group increased their target price on PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a report on Wednesday, December 4th. Cantor Fitzgerald raised their price target on PTC Therapeutics from $76.00 to $113.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Wells Fargo & Company raised their price target on PTC Therapeutics from $56.00 to $68.00 and gave the stock an “overweight” rating in a report on Tuesday, November 26th. JPMorgan Chase & Co. raised their price target on PTC Therapeutics from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, November 19th. Finally, Robert W. Baird raised their price target on PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. Three research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $58.85.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.